Table 2.

Hazard ratios for overall survival in the total patient cohort.

	All patients (N = 912)
	N	Cox proportional hazards model
		Univariable		Multivariable (N = 892)
		HR (95% CI)	p	HR (95% CI)	p
Age
<70	470	1		1
≥70	442	1.52 (1.32–1.75)	<0.001	1.37 (1.18–1.60)	<0.001
Sex
Male	419	1		1
Female	493	0.84 (0.73–0.96)	0.01	0.83 (0.71–0.97)	0.02
ECOG performance status
0–1	519	1		1
2	214	1.85 (1.56–2.20)	<0.001	1.85 (1.55–2.20)	<0.001
3–4	163	3.54 (2.93–4.26)	<0.001	2.95 (2.43–3.58)	<0.001
Missing	16
Primary cancer
Breast	129	1		1
Lung	406	1.45 (1.16–1.80)	<0.001	1.04 (0.81–1.32)	0.77
Colorectal	86	2.20 (1.65–2.95)	<0.001	1.59 (1.15–2.20)	0.01
Melanoma	148	1.28 (0.99–1.67)	0.06	0.81 (0.61–1.09)	0.16
Kidney	32	1.50 (1.00–2.04)	0.05	0.93 (0.59–1.45)	0.74
Others	111	1.55 (1.18–2.04)	0.01	1.09 (0.80–1.49)	0.58
Number of BM
1	324	1		1
2–4	267	1.39 (1.17–1.66)	<0.001	1.40 (1.17–1.68)	<0.001
≥5 (incl lepto)	316	1.94 (1.64–2.29)	<0.001	1.99 (1.66–2.38)	<0.001
Missing	5
Symptomatic
No	161	1		1
Yes	751	1.20 (0.99–1.44)	0.06	1.05 (0.86–1.27)	0.64
ECM status
Controlled	391	1		1
Uncontrolled	521	1.76 (1.53–2.03)	<0.001	1.55 (1.33–1.79)	<0.001
Targetable mutationsa
Yes	448	1		1
No	464	1.46 (1.27–1.68)	<0.001	1.30 (1.11–1.52)	0.001

Estimates from Cox proportional hazards models. The multivariable model comprises all clinical variables included in the unadjusted models. HR: Hazard ratio. CI: Confidence interval. ECM: Extracranial metastases.

^aMutation or positivity for at least one of the following: ALK, EGFR, BRAF, HER-2, KRAS, MSI, NRAS, PD-L1, Progesterone, ROS1, Estrogen.